219 related articles for article (PubMed ID: 17699453)
1. Hemofiltration of recombinant hirudin by different hemodialyzer membranes: implications for clinical use.
Benz K; Nauck MA; Böhler J; Fischer KG
Clin J Am Soc Nephrol; 2007 May; 2(3):470-6. PubMed ID: 17699453
[TBL] [Abstract][Full Text] [Related]
2. Hirudin elimination by hemofiltration: a comparative in vitro study of different membranes.
Frank RD; Farber H; Stefanidis I; Lanzmich R; Kierdorf HP
Kidney Int Suppl; 1999 Nov; (72):S41-5. PubMed ID: 10560804
[TBL] [Abstract][Full Text] [Related]
3. Biological relevance of anti-recombinant hirudin antibodies--results from in vitro and in vivo studies.
Liebe V; Brückmann M; Fischer KG; Haase KK; Borggrefe M; Huhle G
Semin Thromb Hemost; 2002 Oct; 28(5):483-90. PubMed ID: 12420244
[TBL] [Abstract][Full Text] [Related]
4. In vitro studies on hirudin elimination by haemofiltration: comparison of three high-flux membranes.
Frank RD; Farber H; Lanzmich R; Floege J; Kierdorf HP
Nephrol Dial Transplant; 2002 Nov; 17(11):1957-63. PubMed ID: 12401853
[TBL] [Abstract][Full Text] [Related]
5. Anti-hirudin antibodies alter pharmacokinetics and pharmacodynamics of recombinant hirudin.
Fischer KG; Liebe V; Hudek R; Piazolo L; Haase KK; Borggrefe M; Huhle G
Thromb Haemost; 2003 Jun; 89(6):973-82. PubMed ID: 12783109
[TBL] [Abstract][Full Text] [Related]
6. Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study.
Traut M; Haufe CC; Eismann U; Deppisch RM; Stein G; Wolf G
Blood Purif; 2007; 25(5-6):432-40. PubMed ID: 17957097
[TBL] [Abstract][Full Text] [Related]
7. Removal of lepirudin, a recombinant hirudin, by hemodialysis, hemofiltration, or plasmapheresis.
Willey ML; de Denus S; Spinler SA
Pharmacotherapy; 2002 Apr; 22(4):492-9. PubMed ID: 11939684
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes.
Isla A; Gascón AR; Maynar J; Arzuaga A; Corral E; Martín A; Solinís MA; Muñoz JL
Clin Ther; 2005 Sep; 27(9):1444-51. PubMed ID: 16291417
[TBL] [Abstract][Full Text] [Related]
9. Hirudin in renal insufficiency.
Fischer KG
Semin Thromb Hemost; 2002 Oct; 28(5):467-82. PubMed ID: 12420243
[TBL] [Abstract][Full Text] [Related]
10. Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis.
Fischer KG; van de Loo A; Böhler J
Kidney Int Suppl; 1999 Nov; (72):S46-50. PubMed ID: 10560805
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic studies with recombinant hirudin in dogs.
Nowak G; Markwardt F; Fink E
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):70-4. PubMed ID: 2459035
[TBL] [Abstract][Full Text] [Related]
12. The impact of standard high-flux polysulfone versus novel high-flux polysulfone dialysis membranes on inflammatory markers: a randomized, single-blinded, controlled clinical trial.
Kerr PG; Sutherland WH; de Jong S; Vaithalingham I; Williams SM; Walker RJ
Am J Kidney Dis; 2007 Apr; 49(4):533-9. PubMed ID: 17386321
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of cellulose triacetate dialyzer and polysulfone synthetic hemofilter for continuous venovenous hemofiltration in acute renal failure.
Pichaiwong W; Leelahavanichkul A; Eiam-ong S
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S65-72. PubMed ID: 17044456
[TBL] [Abstract][Full Text] [Related]
14. Treatment of hirudin overdosage in a dialysis patient with heparin-induced thrombocytopenia with mixed hemodialysis and hemofiltration treatment.
Mon C; Moreno G; Ortiz M; Diaz R; Herrero JC; Oliet A; Rodriguez I; Ortega O; Gallar P; Vigil A
Clin Nephrol; 2006 Oct; 66(4):302-5. PubMed ID: 17063999
[TBL] [Abstract][Full Text] [Related]
15. Determination of bisphenol a in effluents of hemodialyzers.
Yamasaki H; Nagake Y; Makino H
Nephron; 2001 Aug; 88(4):376-8. PubMed ID: 11474234
[TBL] [Abstract][Full Text] [Related]
16. In vitro study of r-hirudin permeability through membranes of different haemodialysers.
Bucha E; Kreml R; Nowak G
Nephrol Dial Transplant; 1999 Dec; 14(12):2922-6. PubMed ID: 10570098
[TBL] [Abstract][Full Text] [Related]
17. Effect of peracetic acid reprocessing on the transport characteristics of polysulfone hemodialyzers.
Wolff SH; Zydney AL
Artif Organs; 2005 Feb; 29(2):166-73. PubMed ID: 15670286
[TBL] [Abstract][Full Text] [Related]
18. In vitro AN69 and polysulphone membrane permeability to ceftazidime and in vivo pharmacokinetics during continuous renal replacement therapies.
Isla A; Gascón AR; Maynar J; Arzuaga A; Sánchez-Izquierdo JA; Pedraz JL
Chemotherapy; 2007; 53(3):194-201. PubMed ID: 17356270
[TBL] [Abstract][Full Text] [Related]
19. Rotational thrombelastometry for the bedside monitoring of recombinant hirudin.
Sucker C; Zotz RB; Görlinger K; Hartmann M
Acta Anaesthesiol Scand; 2008 Mar; 52(3):358-62. PubMed ID: 18205897
[TBL] [Abstract][Full Text] [Related]
20. Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients.
Isla A; Maynar J; Sánchez-Izquierdo JA; Gascón AR; Arzuaga A; Corral E; Pedraz JL
J Clin Pharmacol; 2005 Nov; 45(11):1294-304. PubMed ID: 16239363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
